Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of St...(OUT THE PROPOSED MERGER. Investors and...),Health

Date:6/18/2009

OUT THE PROPOSED MERGER. Investors and stockholders may obtain, without charge, a copy of the definitive proxy statement/prospectus, as well as other relevant documents containing important information about Wyeth and Pfizer at the SEC's website (http://www.sec.gov). Wyeth's stockholders also may obtain, without charge, a copy of the definitive proxy statement/prospectus and other relevant documents by directing a request by mail or telephone to Wyeth, Five Giralda Farms, Madison, NJ 07940, Attention: Investor Relations, (877) 552-4744.

Wyeth and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Wyeth's stockholders with respect to the proposed merger. Information about Wyeth's directors and executive officers and their ownership of Wyeth's common stock is set forth in Wyeth's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as amended by Wyeth's Annual Report on Form 10-K/A, which was filed with the SEC on February 27, 2009 and April 30, 2009, respectively, and the definitive proxy statement/prospectus for Wyeth's 2009 Annual Meeting of Stockholders, which was filed with the SEC on Schedule 14A on June 17, 2009. Stockholders may obtain additional information regarding the interests of Wyeth and its directors and executive officers in the proposed merger, which may be different than those of Wyeth's stockholders generally, by reading the definitive proxy statement/prospectus and other relevant documents regarding the proposed merger.

'/>"/>

SOURCE Wyeth Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
2. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
3. DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza
4. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
5. U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth
6. Wyeth Reports Earnings Results for the 2009 First Quarter
7. Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB
8. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
9. Wyeth Reduces Risk with Dyadem Software
10. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
11. FDA Approves New Indication for Wyeths TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia